ChartRow logo
Data provided bySource: Twelve Data
CRL
$337.52+7.83%
as of close, Nov 6, 2026
☾ AH $337.52 +7.83%
PeersRVTYMEDPICLRIQVGHILMN
Share this page

CRL — Charles River Laboratories price, chart and key statistics

Technical analysis2
Overlay lines0
Addendum charts0
Data provided bySource: Twelve Data
What would $1,000 invested in CRL be worth today? →
CRL returns: By year · By month · By week · Trailing

Price data

Price
$337.52
YTD price return
+69.20%
YTD total return
+69.20%
Market cap
16.2B
Enterprise value
18.9B
Shares outstanding
47.9M
52W low
$146.20
52W high
$379.63
From 52W high
-11.09%
From 52W low
+130.86%
52W range
82%$146–$380
Beta
1.37

Volume

Rel volume
0.90×
30D volume
1.2M
30D $ vol
386M

Insider trading

Insider net 1W
none
Insider net 1M
−$9.2M
Insider net 3M
−$31.0M
Insider net 1Y
−$52.1M

Form 4 transactions by trade date, as filed; latest on file 2026-10-22.

Fundamentals

Sales (ttm)
4B
Sales/share
$82.99
EPS (ttm)
$0.83
FCF (ttm)
399.6M
FCF/share
$8.34
Book value/share
$67.35
Net margin
1.01%
ROE
1.25%
ROA
0.54%
Debt / equity
0.76×
Current ratio
1.41

Growth (CAGR, ttm) · 10Y

Sales
-1.17%-1.93%+3.03%+9.75%
Net income
n/a-56.22%-36.73%-11.85%
FCF
-26.57%+2.75%-2.43%+5.11%
Shares
-2.65%-2.25%-1.03%+0.12%

Per-share growth (CAGR, ttm) · 10Y

EPS
n/a-55.36%-36.04%-11.99%
Sales/share
+1.52%+0.33%+4.10%+9.61%
FCF/share
-24.57%+5.12%-1.42%+4.98%
Book value/share
-2.68%+1.48%+6.97%+13.89%
Price
+97.61%+23.00%-2.10%+17.34%
Total return
+97.61%+23.00%-2.10%+17.34%

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)
407.8×
P/OI (ttm)
101.7×
Fwd P/E
26.5×
P/S (ttm)
4.1×
P/B (mrq)
5.0×
P/FCF (ttm)
40.5×
EV/EBITDA (fy)
42.6×
EV/Sales (ttm)
4.8×
FCF yield (ttm)
2.47%
Buyback yield (realized, 1y)
2.65%
Shareholder yield (realized, 1y)
2.65%
Buyback yield (cash, ttm)
2.00%
Shareholder yield (cash, ttm)
2.00%

Vs own 10Y history

P/E
99th
P/OI
92nd
P/S
86th
P/B
71st
P/FCF
94th

Bar = where today’s multiple sits in CRL’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).

Performance · price returntotal return · as of 2026-11-06#

Data provided bySource: Twelve Data
1D
+7.83%
5D
-6.09%
1M
+10.68%
3M
+27.12%
YTD
+69.20%
1Y
+97.52%
5Y
-10.05%
1D
+7.83%
5D
-6.09%
1M
+10.68%
3M
+27.12%
YTD
+69.20%
1Y
+97.52%
5Y
-10.05%

Fundamentals#

Revenue

5Y CAGR +6.5%10Y CAGR +11.4%YoY −2.2%
$4B TTM$982.7M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating income

5Y CAGR −43.4%10Y CAGR −19.0%YoY +51.4%
$159M TTM$202.6M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

EPS (diluted)

5Y n/m10Y n/mYoY +523.6%
$0.83 TTM$6.86 Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Free cash flow

5Y CAGR +6.4%10Y CAGR +7.8%YoY +16.3%
$399.6M TTM$207.3M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM

TTM: operating cash flow $622.4M, capex −$222.8M

Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Q3 2026: operating cash flow $254.1M, capex −$46.8M

Shares (diluted)

5Y −2.1%10Y +4.1%YoY −1.7%
48.6M TTM48.6M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Net income

5Y n/m10Y n/mYoY +512.0%
$40.2M TTM$333.1M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Full CRL financials →

About Charles River Laboratories#

Data provided bySource: Twelve Data

Charles River Laboratories International, Inc. is a life sciences company that provides products and services supporting pharmaceutical and biotechnology research, drug discovery, non-clinical development, and safety assessment. Its Research Models and Services business supplies purpose-bred rodents and genetically defined research models, along with related services used in laboratory and preclinical studies. Through Discovery and Safety Assessment, the company conducts regulated and non-regulated in vitro, in vivo, and in silico studies, laboratory support, consulting, and program management for potential medicines. Its Manufacturing Solutions activities include microbial testing and biologics-related services that help address quality, contamination control, and development requirements. Charles River Laboratories International, Inc. serves pharmaceutical and biotechnology companies, government agencies, academic institutions, and other research organizations across international life sciences markets. Its integrated role connects early laboratory research with the testing and development processes required to advance medical products toward regulatory review.

Wilmington, MA·18,300 employees·Diagnostics & Research·criver.com·As of Oct 28, 2026

Recent filings#

All filings and insider trades →

ETFs holding CRL#

28 of the 193 ETFs ChartRow carries live hold CRL. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).

FundNameFiled weight
IBBiShares Biotechnology ETF0.8%
RSPInvesco S&P 500 Equal Weight ETF0.2%
VBRVanguard Small-Cap Value ETF0.2%
VHTVanguard Health Care ETF0.2%
XLVHealth Care Select Sector SPDR Fund0.2%
VBVanguard Small-Cap ETF0.1%
IWSiShares Russell Mid-Cap Value ETF0.1%
IWRiShares Russell Midcap ETF0.1%
TickerName1M1D
LLYEli Lilly and Company+16.98%-0.79%
JNJJohnson & Johnson+8.42%+1.43%
ABBVAbbVie Inc.+9.23%+1.07%
MRKMerck & Co. Inc.+3.37%-0.14%
UNHUnitedHealth Group Incorporated Common Stock (DE)+4.74%-0.40%
NVSNovartis AG+15.46%+0.38%
TMOThermo Fisher Scientific Inc.+5.81%+2.63%
AMGNAmgen Inc.+14.36%+0.03%